BURLINGTON, Mass. & NEW YORK–(BUSINESS WIRE)–$BFLY #POCUS—Butterfly Network, Inc. (NYSE: BFLY) (“Butterfly”), a pioneer and leader in semiconductor-based ultrasound devices, programmable cloud software and AI, announced that it will report second quarter 2026 financial results on Thursday, July 30, 2026, at 8:00 am ET.
Joseph DeVivo, President, Chief Executive Officer and Chairman of the Board, and John Doherty, Executive Vice President and Chief Financial Officer, will host a conference call and webcast before the market opens on July 30 to discuss the financial performance and operational progress.
The conference call will be broadcast live in listen-only mode via a webcast on Butterfly’s Investor Relations website at Events & Presentations.
Individuals interested in listening to the conference call via telephone may do so by dialing approximately ten minutes prior to start time:
United States (Local): +1 646 844 6383
United States (Toll-Free): +1 833 470 1428
Global Dial-In Numbers: https://www.netroadshow.com/events/global-numbers?confId=48643
Access Code: 424023
After the live webcast, the call will be archived on Butterfly’s Investor Relations events page. In addition, a telephone replay of the call will be available until August 6, 2026, by dialing:
United States (Local): +1 929 458 6194
United States (Toll-Free): +1 866 813 9403
Access Code: 941825
About Butterfly Network
Butterfly Network, Inc. (NYSE: BFLY) is driving a digital revolution in ultrasound imaging and sensing with its proprietary Ultrasound-on-Chip™ semiconductor technology and software solutions. Butterfly first proved its technology in the point-of-care ultrasound market – commercializing the world’s first single-probe, whole-body portable ultrasound device, which is now on its best-selling, third-generation: Butterfly iQ3™. The Company combines its advanced hardware with cloud software and AI, an enterprise workflow solution (Compass AI™) and other offerings to drive adoption of affordable, accessible ultrasound. Butterfly also enables third-party development of imaging AI apps through Butterfly Garden™, its software development kit and AI marketplace.
In addition to its medical imaging products, Butterfly Embedded™ is the Company’s Ultrasound-on-Chip™ licensing and co-development business designed to enable a new wave of ultrasound-enabled technologies across non-competitive healthcare markets and beyond. Through Butterfly Embedded™, partners can build and scale novel ultrasound applications powered by Butterfly’s proprietary semiconductor chip and software platform.
Butterfly’s innovations have been recognized by Prix Galien USA, Fierce 50, TIME’s Best Inventions and Fast Company’s World Changing Ideas, among other achievements. To learn more, visit: www.butterflynetwork.com
Contacts
Investors:
John Doherty
Chief Financial Officer, Butterfly
[email protected]
